Evidence map›Paper›PMID 38969656›Full record

ArticleScientific reports2024

3D engineered scaffold for large-scale Vigil immunotherapy production.

Fabienne Kerneis, Ernest Bognar, Laura Stanbery, Seongjun Moon, Do Hoon Kim, Yuxuan Deng, Elliot Hughes, Tae-Hwa Chun, Darron Tharp, Heidi Zupanc and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fabienne KerneisGradalis, Inc, Dallas, TX, 75006, USA.
Ernest BognarGradalis, Inc, Dallas, TX, 75006, USA.
Laura StanberyGradalis, Inc, Dallas, TX, 75006, USA.
Seongjun MoonUniversity of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.
Do Hoon KimUniversity of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.
Yuxuan DengUniversity of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.
Elliot HughesUniversity of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.
Tae-Hwa ChunUniversity of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.
Darron TharpGradalis, Inc, Dallas, TX, 75006, USA.
Heidi ZupancGradalis, Inc, Dallas, TX, 75006, USA.
Chris JayGradalis, Inc, Dallas, TX, 75006, USA.
Adam WalterGradalis, Inc, Dallas, TX, 75006, USA.
John NemunaitisGradalis, Inc, Dallas, TX, 75006, USA. jnemunaitis@gradalisinc.com.
Joerg LahannUniversity of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we reported successful cellular expansion of a murine colorectal carcinoma cell line (CT-26) using a three-dimensional (3D) engineered extracellular matrix (EECM) fibrillar scaffold structure. CCL-247 were grown over a limited time period of 8 days on 3D EECM or tissue culture polystyrene (TCPS). Cells were then assayed for growth, electroporation efficiency and Vigil manufacturing release criteria. Using EECM scaffolds, we report an expansion of CCL-247 (HCT116), a colorectal carcinoma cell line, from a starting concentration of 2.45 × 10

Indexed as

Extracellular MatrixImmunotherapyTissue ScaffoldsAnimalsCell Culture Techniques, Three DimensionalCell Line, TumorCell ProliferationColorectal NeoplasmsHCT116 CellsHumansMiceTissue EngineeringAutologous tumor cell therapyCell expansionImmunotherapyOvarian cancerVigil

Identifiers

PMID38969656
PMCPMC11226630

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.